Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06612645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Study acronym: CMD03
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 1, 2026 to Dec 1, 2027
    • Study completion date: Dec 1, 2027 to Dec 1, 2028
    v6
  2. Study sites: 2 to 1v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2024 to Apr 1, 2025
    • Study sites: 1 to 2
    v4
  4. Study title shortened, about 1 wordv3
  5. Study title revisedv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
Trial Details
NCT Number NCT06612645
Lead Sponsor Chulalongkorn University
Collaborators: King Chulalongkorn Memorial Hospital
Conditions
(from sponsor)		 Pediatric Cancers, Solid Tumor Pediatric
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov